Аллерген-специфическая иммунотерапия у детей (на правах руководства). Согласительный документ Ассоциации детских аллергологов и иммунологов России. Ю. С. Смолкин
Чтение книги онлайн.
Читать онлайн книгу Аллерген-специфическая иммунотерапия у детей (на правах руководства). Согласительный документ Ассоциации детских аллергологов и иммунологов России - Ю. С. Смолкин страница 12
5. Głobińska A, Boonpiyathad T, Satitsuksanoa P, Kleuskens M, van de Veen W, Sokolowska M, Akdis M. Mechanisms of allergen-specific immunotherapy: Diverse mechanisms of immune tolerance to allergens. Ann Allergy Asthma Immunol. 2018;121 (3):306—312.
6. Berings M, Karaaslan C, Altunbulakli C, Gevaert P, Akdis M, Bachert C, Akdis CA. Advances and highlights in allergen immunotherapy: On the way to sustained clinical and immunologic tolerance. J Allergy Clin Immunol. 2017;140 (5):1250—1267.
7. Novak N, Mete N, Bussmann C, Maintz L, Bieber T, Akdis M et al. Early suppression of basophil activation during allergen-specific immunotherapy by histamine receptor 2. J Allergy Clin Immunol. 2012; 130: 1153—1158.
8. Clay CD, Strait RT, Mahler A, Khodoun MV, Finkelman FD. Anti-FcγRIIB monoclonal antibody suppresses murine IgG-dependent anaphylaxis by Fc domain targeting of FcγRIII. J Allergy Clin Immunol. 2018;141 (4):1373—1381.
9. MacGlashan J, Hamilton RG. Parameters determining the efficacy of CD32 to inhibit activation of FcepsilonRI in human basophils. J Allergy Clin Immunol. 2016; 137: 1256—1258.
10. Legoux FP, Lim JB, Cauley AW et al. CD4+ T cell tolerance to tissue-restricted self antigens is mediated by antigen-specific regulatory T cells rather than deletion. Immunity. 2015;43:896—908.
11. Meiler F, Zumkehr J, Klunker S, Ruckert B, Akdis CA, Akdis M. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med. 2008;205 (12):2887—2898.
12. Ryan JF, Hovde R, Glanville J, Lyu SC, Ji X, Gupta S et al. Successful immunotherapy induces previously unidentified allergen-specific CD4+ T-cell subsets. Proc Natl Acad Sci USA. 2016;113:E1286-E1295.
13. Suarez-Fueyo A, Ramos T, Galan A et al. Grass tablet sublingual immunotherapy downregulates the TH2 cytokine response followed by regulatory T-cell generation. J Allergy Clin Immunol. 2014;133:130—138.
14. Boonpiyathad T, Sokolowska M, Morita H, et al. Der p 1-specific regulatory T-cell response during house dust mite allergen immunotherapy. Allergy. 2019;74:976—985.
15. Palomares O, Martin-Fontecha M, Lauener R, et al. Regulatory T cells and immune regulation of allergic diseases: roles of IL-10 and TGF-beta. Genes Immun. 2014;15 (8):511—520.
16. Boonpiyathad T, Sokolowska M, Morita H, et al. Der p 1-specific regulatory T-cell response during house dust mite allergen immunotherapy. Allergy. 2019;74:976—985.
17. Ihara F, Sakurai D, Yonekura S, et al. Identification of specifically reduced Th2 cell subsets in allergic rhinitis patients after sublingual immunotherapy. Allergy. 2018;73 (9):1823—1832.
18. Layhadi JA, Eguiluz-Gracia I, Shamji MH. Role of IL-35 in sublingual allergen immunotherapy. Curr Opin Allergy Clin Immunol. 2019;19 (1):12—17.
19. Tordesillas L, Mondoulet L, Blazquez AB, Benhamou PH, Sampson HA, Berin MC. Epicutaneous immunotherapy induces gastrointestinal LAP+ regulatory T cells and prevents food-induced anaphylaxis. J Allergy Clin Immunol. 2017;139:189—201.
20. van de Veen W, Wirz OF, Globinska A, Akdis M. Novel mechanisms in immune tolerance to allergens during natural allergen exposure and allergen-specific immunotherapy. Curr Opin Immunol. 2017;48:74—81.
21. Stanic B, van de Veen W, Wirz OF et al. IL-10-overexpressing B cells regulate innate and adaptive immune responses. J Allergy Clin Immunol. 2015;135:771—780.
22. Boonpiyathad T, Meyer N, Moniuszko M et al. High-dose bee venom exposure induces similar tolerogenic B-cell responses in allergic patients and healthy beekeepers. Allergy. 2017;72:407—415.
23. Patil SU, Ogunniyi AO, Calatroni A et al. Peanut oral immunotherapy transiently expands circulating Ara h 2-specific B cells with a homologous repertoire in unrelated subjects. J Allergy Clin Immunol. 2015;136:125—134.
24. Shamji MH, Kappen JH, Akdis M et al. Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper. Allergy. 2017;72:1156—1173.
25. Pulendran B, Tang H, Manicassamy S. Programming dendritic cells to induce T (H) 2 and tolerogenic responses. Nat Immunol. 2010;11 (8):647—655.
26. Gordon JR, Ma Y, Churchman L, Gordon SA, Dawicki W. Regulatory dendritic cells for immunotherapy in immunologic diseases. Front Immunol. 2014;5:7.
27. Sun W, Wei JW, Li H, Wei FQ, Li J, Wen WP. Adoptive cell therapy of tolerogenic dendritic cells as inducer of regulatory T cells in allergic rhinitis. International forum of allergy & rhinology. 2018;8 (11):1291—1299.
28. Tanaka Y, Nagashima H, Bando K et al. Oral CD103 (-) CD11b (+) classical dendritic cells present sublingual antigen and induce Foxp3 (+) regulatory T cells in draining lymph nodes. Mucosal Immunol. 2017;10:79—90.
29. Deniz G, Akdis M, Aktas E, Blaser K, Akdis CA. Human NK1 and NK2 subsets determined by purification of IFN-gammasecreting and IFN-gamma-nonsecretingNK cells. Eur J Immunol. 2002;32 (3):879—884.
30. Deniz G, Erten G, Kucuksezer UC, et al. Regulatory NK cells suppress antigenspecific T cell responses. J Immunol. 2008;180 (2):850—857.
31. Ferstl R, Frei R, Barcik W, et al. Histamine receptor 2 modifies iNKT cell activity within the inflamed lung. Allergy. 2017;72 (12):1925—1935.
32. Globinska A, Kowalski ML. Innate lymphoid cells: the role in respiratory infections and lung tissue damage. Exp Rev Clin Immunol. 2017;13 991—999.
33. Kortekaas Krohn I, Shikhagaie MM, Golebski K, et al. Emerging roles of innate lymphoid cells in inflammatory diseases: Clinical implications. Allergy. 2018;73 (4):837—850.
34. Lao-Araya M, Steveling E, Scadding GW, Durham SR, Shamji MH. Seasonal increases in peripheral innate lymphoid type 2 cells are inhibited by subcutaneous grass pollen immunotherapy. J Allergy Clin Immunol. 2014;134 (5):1193—1195.
35. Fan DC, Wang XD, Wang CS, Wang Y, Cao FF, Zhang L. Suppression of immunotherapy on group 2 innate lymphoid cells in allergic rhinitis. Chin Med J (Engl). 2016;129:2824—2828.
36. Morita H, Kubo T, Ruckert B, et al. Induction of human regulatory innate lymphoid cells from group 2 innate lymphoid cells by retinoic acid. J Allergy Clin Immunol. 2019;143:2190—2201.
37. Wang S, Xia P, Chen Y, et al. Regulatory Innate Lymphoid Cells Control Innate Intestinal Inflammation. Cell. 2017;171 (1):201—216.
38. Scadding GW, Calderon MA, Shamji MH et al. Effect of 2 years of treatment with sublingual grass pollen immunotherapy on nasal response to allergen challenge at 3 years among patients with moderate to severe seasonal allergic rhinitis: The GRASS randomized clinical trial. JAMA. 2017;317:615—625.
39. Freiberger SN, Zehnder M, Gafvelin G, Gronlund H, Kundig TM, Johansen P. IgG4 but no IgG1 antibody production after intralymphatic immunotherapy with recombinant MAT-Feld1 in human. Allergy. 2016; 71: 1366—1370.
40. Orengo JM, Radin AR, Kamat V et al. Treating cat allergy with monoclonal IgG antibodies that bind allergen